Share this news

Prescription of anti-Alzheimer medications to persons with mild cognitive impairment (MCI) is low in France

November 15, 2013
In France prescription of drugs for Alzheimer’s disease (AD) is strictly regulated. The Department of Public Health and the Memory Clinic of Nice University Hospital have explored real world prescriptions of anti-AD medications in patients with mild cognitive impairment (MCI) not AD. A national survey [1] was set up from the data of the French National Alzheimer Databank (BNA) and shows that off label prescriptions are not frequent and concern 6.1% of MCI patients (versus a quarter of MCI patients in the US [2]). French physicians seem to limit this kind of prescription to MCI patients at risk of conversion to AD: more aged, with a more important quantitative cognitive impairment and with a memory predominant form. In a context of low efficacy of the available medications against AD this study emphasizes the need to develop more preventive drugs.

About Mild Cognitive Impairment (MCI):

Mild Cognitive Impairment is a frequent cause of consultation in memory clinics. It is characterized by a change in cognition skills (memory, attention, language, executive functions, visuospatial skills…) and would affect 10 to 20% of persons aged of 70 and more. Causes of MCI are various and evolution rates to AD ranges from 10% to 20% per year. There are no specific drugs against MCI to date but non pharmacologic cognitive stimulation techniques and global medical support are useful.

About the French National Alzheimer Databank (Banque Nationale Alzheimer, BNA)

The BNA was one of the measures of the French National Plan for “Alzheimer Disease and related disorders”. This measure describes the setting up of a nationwide system for collecting activity data and for epidemiological surveillance and follow-up within specialized centers. The BNA is managed by the Nice University Hospital.

[1] Mild Cognitive Impairment and Anti-Alzheimer Disease Medications: A Cross Sectional Study of the French National Alzheimer Databank (BNA). Tifratene K, Sakarovitch C, Rouis A, Pradier C, Robert P. J Alzheimers Dis. 2013 Sep 9, In press.

[2] Treatment practices of mild cognitive impairment in California Alzheimer’s Disease Centers. Weinstein AM, Barton C, Ross L, Kramer JH, Yaffe K. J Am Geriatr Soc. 2009;57(4):686-90.